TABLE 1.
Framework Mean Scores for 15 Drugs, Overall, and by Subdomaina
| ASCO | ESMO | ICER | NCCN | |||||
|---|---|---|---|---|---|---|---|---|
| Breast Cancer Drugs | ||||||||
| Overall, mean (SD) | ||||||||
| A | 53.51 | (9.17) | 2.75 | (0.71) | 3.44 | (0.42) | 3.41 | (0.46) |
| B | 16.45 | (2.38) | 1.63 | (0.52) | 3.00 | (0.53) | 3.38 | (0.42) |
| C | 55.26 | (14.27) | 2.25 | (0.71) | 1.88 | (1.55) | 3.34 | (0.30) |
| D | 43.19 | (5.42) | 4.75 | (0.46) | 3.81 | (0.26) | 3.75 | (0.50) |
| E | 36.25 | (5.50) | 3.88 | (0.35) | 3.63 | (0.52) | 3.97 | (0.53) |
| Clinical benefit | ||||||||
| A | 42.53 | (4.27) | 3.00 | (0.00) | - | (-) | 3.13 | (0.99) |
| B | 19.00 | (0.00) | 1.63 | (0.52) | - | (-) | 3.25 | (0.89) |
| C | 54.50 | (11.22) | 3.00 | (0.00) | - | (-) | 3.13 | (0.35) |
| D | 32.00 | (0.00) | 3.88 | (0.35) | - | (-) | 3.50 | (0.53) |
| E | 32.00 | (0.00) | 3.75 | (0.71) | - | (-) | 4.13 | (0.64) |
| Toxicity | ||||||||
| A | 2.99 | (1.69) | 0.00 | (0.00) | - | (-) | 3.00 | (0.76) |
| B | -2.56 | (2.38) | 0.00 | (0.00) | - | (-) | 2.75 | (0.71) |
| C | -9.74 | (4.64) | -0.13 | (0.35) | - | (-) | 2.88 | (0.83) |
| D | 1.19 | (0.96) | 0.00 | (0.00) | - | (-) | 3.88 | (0.64) |
| E | -0.65 | (1.05) | 0.00 | (0.00) | - | (-) | 3.38 | (0.74) |
| Quality of life | ||||||||
| A | 0.00 | (0.00) | 0.13 | (0.35) | - | (-) | - | (-) |
| B | 0.00 | (0.00) | 0.00 | (0.00) | - | (-) | - | (-) |
| C | 1.25 | (3.54) | 0.00 | (0.00) | - | (-) | - | (-) |
| D | 7.50 | (4.63) | 0.63 | (0.52) | - | (-) | - | (-) |
| E | 1.25 | (3.54) | 0.00 | (0.00) | - | (-) | - | (-) |
| Certaintyb | ||||||||
| A | - | (-) | - | (-) | 1.88 | (0.35) | 3.75 | (0.46) |
| B | - | (-) | - | (-) | 2.25 | (0.46) | 3.75 | (0.53) |
| C | - | (-) | - | (-) | 2.25 | (0.89) | 3.69 | (0.46) |
| D | - | (-) | - | (-) | 1.38 | (0.52) | 3.81 | (0.59) |
| E | - | (-) | - | (-) | 1.63 | (0.74) | 4.19 | (0.70) |
| Lung Cancer Drugs | ||||||||
| Overall, mean(SD) | ||||||||
| F | 73.08 | (13.20) | 4.00 | (0.00) | 3.63 | (0.35) | 3.66 | (0.52) |
| G | 73.85 | (6.23) | 3.38 | (0.74) | 3.63 | (0.23) | 3.66 | (0.76) |
| H | 63.81 | (11.27) | 4.88 | (0.35) | 3.75 | (0.27) | 3.94 | (0.46) |
| I | 40.95 | (10.65) | 2.75 | (0.46) | 3.19 | (0.53) | 3.72 | (0.59) |
| J | 11.49 | (8.77) | 2.00 | (0.76) | 3.19 | (0.46) | 3.69 | (0.53) |
| Clinical benefit | ||||||||
| F | 45.38 | (3.89) | 3.00 | (0.00) | - | (-) | 3.38 | (0.52) |
| G | 50.35 | (0.14) | 3.00 | (0.00) | - | (-) | 3.13 | (0.99) |
| H | 41.00 | (0.00) | 4.00 | (0.00) | - | (-) | 3.75 | (0.89) |
| I | 29.00 | (0.00) | 2.00 | (0.00) | - | (-) | 3.50 | (0.93) |
| J | 21.00 | (0.00) | 2.00 | (0.76) | - | (-) | 3.25 | (0.89) |
| Toxicity | ||||||||
| F | 0.71 | (2.56) | 0.13 | (0.35) | - | (-) | 3.38 | (0.92) |
| G | 3.00 | (3.79) | 0.50 | (0.53) | - | (-) | 3.50 | (0.93) |
| H | 13.31 | (4.20) | 0.88 | (0.35) | - | (-) | 4.13 | (0.64) |
| Lung Cancer Drugs | ||||||||
| Toxicity | ||||||||
| I | 2.45 | (7.60) | 0.75 | (0.46) | - | (-) | 3.63 | (0.92) |
| J | -16.52 | (4.85) | 0.00 | (0.00) | - | (-) | 3.38 | (0.74) |
| Quality of life | ||||||||
| F | 8.75 | (3.54) | 1.00 | (0.00) | - | (-) | - | (-) |
| G | 6.25 | (5.18) | 0.00 | (0.00) | - | (-) | - | (-) |
| H | 0.00 | (0.00) | 0.00 | (0.00) | - | (-) | - | (-) |
| I | 0.00 | (0.00) | 0.00 | (0.00) | - | (-) | - | (-) |
| J | 0.00 | (0.00) | 0.00 | (0.00) | - | (-) | - | (-) |
| Certaintyb | ||||||||
| F | - | (-) | - | (-) | 1.50 | (0.53) | 3.94 | (0.62) |
| G | - | (-) | - | (-) | 1.75 | (0.46) | 4.00 | (0.76) |
| H | - | (-) | - | (-) | 1.50 | (0.53) | 3.94 | (0.68) |
| I | - | (-) | - | (-) | 1.75 | (0.71) | 3.88 | (0.52) |
| J | - | (-) | - | (-) | 2.00 | (0.53) | 4.06 | (0.68) |
| Prostate Cancer Drugs | ||||||||
| Overall, mean (SD) | ||||||||
| K | 47.90 | (7.05) | 4.63 | (0.74) | 3.56 | (0.32) | 3.75 | (0.53) |
| L | 37.67 | (12.30) | 2.50 | (0.76) | 2.44 | (0.90) | 3.34 | (0.42) |
| M | 37.41 | (10.16) | 2.25 | (0.46) | 3.00 | (0.53) | 3.72 | (0.49) |
| N | 51.65 | (13.54) | 4.13 | (0.35) | 3.81 | (0.26) | 3.94 | (0.53) |
| O | -5.76 | (20.15) | 1.13 | (0.35) | 0.63 | (0.74) | 3.13 | (0.57) |
| Clinical benefit | ||||||||
| K | 35.00 | (0.00) | 3.63 | (0.74) | - | (-) | 3.50 | (0.53) |
| L | 30.00 | (0.00) | 2.38 | (0.74) | - | (-) | 3.38 | (0.92) |
| M | 24.00 | (0.00) | 1.50 | (0.53) | - | (-) | 3.25 | (0.71) |
| N | 35.67 | (16.92) | 3.13 | (0.35) | - | (-) | 3.63 | (0.52) |
| O | -9.77 | (16.56) | 1.00 | (0.00) | - | (-) | 2.25 | (1.28) |
| Toxicity | ||||||||
| K | -2.10 | (2.17) | 0.00 | (0.00) | - | (-) | 3.63 | (0.92) |
| L | -3.58 | (3.64) | 0.00 | (0.00) | - | (-) | 2.63 | (0.74) |
| M | -1.59 | (4.59) | 0.00 | (0.00) | - | (-) | 3.50 | (0.93) |
| N | -4.78 | (2.08) | 0.00 | (0.00) | - | (-) | 4.00 | (0.76) |
| O | 1.51 | (2.81) | 0.00 | (0.00) | - | (-) | 3.00 | (0.76) |
| Quality of life | ||||||||
| K | 10.00 | (0.00) | 1.00 | (0.00) | - | (-) | - | (-) |
| L | 0.00 | (0.00) | 0.00 | (0.00) | - | (-) | - | (-) |
| M | 7.50 | (4.63) | 0.75 | (0.46) | - | (-) | - | (-) |
| N | 10.00 | (0.00) | 1.00 | (0.00) | - | (-) | - | (-) |
| O | 1.25 | (3.54) | 0.00 | (0.00) | - | (-) | - | (-) |
| Certaintyb | ||||||||
| K | - | (-) | - | (-) | 1.63 | (0.52) | 3.94 | (0.62) |
| L | - | (-) | - | (-) | 1.88 | (0.83) | 3.69 | (0.46) |
| M | - | (-) | - | (-) | 1.75 | (0.89) | 4.06 | (0.56) |
| N | - | (-) | - | (-) | 1.38 | (0.52) | 4.06 | (0.73) |
| O | - | (-) | - | (-) | 1.75 | (1.04) | 3.63 | (0.35) |
aAssessments from 8 panelists for each drug and framework; N = 480 total assessments.
bIn the certainty subdomain for ICER, lower scores represent higher rankings.
ASCO = American Society of Clinical Oncology; ESMO = European Society for Medical Oncology; ICER = Institute for Clinical and Economic Review; NCCN = National Comprehensive Cancer Network; SD = standard deviation.